Both NLRP3 and IL-1 inhibition alleviated hyperalgesia and decreased the increase in biomarkers such as p-ERK, c-Fos and CGRP associated with central sensitization of CM in the TNC. The NLRP3 inflammasome may be a target for controlling CM-associated pain, and inhibiting it may represent a novel therapeutic rationale and technique for migraine treatment. Here, NLRP3 is linked to migraine disorder.